Additional file 1: of Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016Satoshi Ikeda, Terufumi Kato, Takashi Ogura, Akimasa Sekine, , Noriyuki Masuda, Satoshi Igawa, Ken Katono, Sakiko Otani, , Haruhiro Saito, Tetsuro Kondo, Yukio Hosomi, Yoshiro Nakahara, Masanori Nishikawa, Keiko Utumi, Yuki Misumi, , Kentaro Sakamaki & Hiroaki Okamoto
Figure S1. Trial profile. Abbreviations: CEC, circulating endothelial cell. (JPEG 147Â kb)
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.